Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 385352, 12 pages
http://dx.doi.org/10.1155/2014/385352
Research Article

TNFα Promotes Th17 Cell Differentiation through IL-6 and IL-1β Produced by Monocytes in Rheumatoid Arthritis

1Shanghai Institute of Immunology, Institutes of Medical Sciences, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China
2Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Shanghai 200092, China
3School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China
4Guanghua Integrative Medicine Hospital, 540 Xinhua Road, Shanghai 200052, China
5Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, 540 Xinhua Road, Shanghai 200052, China

Received 11 July 2014; Accepted 12 October 2014; Published 11 November 2014

Academic Editor: Xiao-Feng Yang

Copyright © 2014 Yingxia Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Feldmann, F. M. Brennan, and R. N. Maini, “Rheumatoid arthritis,” Cell, vol. 85, no. 3, pp. 307–310, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Ali, F. Ponchel, K. E. Wilson et al., “Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy,” Journal of Clinical Investigation, vol. 107, no. 4, pp. 519–528, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Shahrara, Q. Huang, A. M. Mandelin II, and R. M. Pope, “TH-17 cells in rheumatoid arthritis,” Arthritis Research and Therapy, vol. 10, no. 4, article R93, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Ramesh and W. B. Reeves, “TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity,” The Journal of Clinical Investigation, vol. 110, no. 6, pp. 835–842, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Feldmann, “Development of anti-TNF therapy for rheumatoid arthritis,” Nature Reviews Immunology, vol. 2, no. 5, pp. 364–371, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Geiler, M. Buch, and M. F. Mcdermott, “Anti-TNF treatment in rheumatoid arthritis,” Current Pharmaceutical Design, vol. 17, no. 29, pp. 3141–3154, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. A. Smith, T. Farrah, and R. G. Goodwin, “The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death,” Cell, vol. 76, no. 6, pp. 959–962, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Sohn, A. Lee, Y. Qiao, K. Loupasakis, L. B. Ivashkiv, and G. D. Kalliolias, “Prolonged TNFα primes fibroblast-like synoviocytes in a gene-specific manner by altering chromatin,” Arthritis & Rheumatology, 2014. View at Publisher · View at Google Scholar
  9. A. J. Puren, G. Fantuzzi, Y. Gu, M. S.-S. Su, and C. A. Dinarello, “Interleukin-18 (IFNγ-inducing factor) induces IL-8 and IL-1β via TNFα production from non-CD14+ human blood mononuclear cells,” Journal of Clinical Investigation, vol. 101, no. 3, pp. 711–721, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. B. K. Popivanova, K. Kitamura, Y. Wu et al., “Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis,” The Journal of Clinical Investigation, vol. 118, no. 2, pp. 560–570, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Burstein and E. R. Fearon, “Colitis and cancer: a tale of inflammatory cells and their cytokines,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 464–467, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Wicovsky, F. Henkler, S. Salzmann, P. Scheurich, C. Kneitz, and H. Wajant, “Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation,” Oncogene, vol. 28, no. 15, pp. 1769–1781, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P. E. Lipsky, D. M. F. M. van der Heijde, E. W. St. Clair et al., “Infliximab and methotrexate in the treatment of rheumatoid arthritis,” The New England Journal of Medicine, vol. 343, no. 22, pp. 1594–1602, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. J. S. Smolen and P. Emery, “Infliximab: 12 years of experience,” Arthritis Research and Therapy, vol. 13, no. 1, article S2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. F. M. Brennan and I. B. McInnes, “Evidence that cytokines play a role in rheumatoid arthritis,” The Journal of Clinical Investigation, vol. 118, no. 11, pp. 3537–3545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Miossec, “Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified,” Arthritis & Rheumatism, vol. 56, no. 7, pp. 2111–2115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. I. Koenders, E. Lubberts, F. A. J. van de Loo et al., “Interleukin-17 acts independently of TNF-α under arthritic conditions,” Journal of Immunology, vol. 176, no. 10, pp. 6262–6269, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Zhang, G. Ren, M. Guo et al., “Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model,” International Immunopharmacology, vol. 15, no. 2, pp. 199–205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Veldhoen, R. J. Hocking, R. A. Flavell, and B. Stockinger, “Signals mediated by transforming growth factor-β initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease,” Nature Immunology, vol. 7, no. 11, pp. 1151–1156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Bettelli, Y. Carrier, W. Gao et al., “Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells,” Nature, vol. 441, no. 7090, pp. 235–238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Kebir, K. Kreymborg, I. Ifergan et al., “Transforming growth factor-beta induces development of the T(H)17 lineage,” Nature, vol. 441, no. 7090, pp. 231–234, 2006. View at Google Scholar
  22. H. G. Evans, N. J. Gullick, S. Kelly et al., “In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 15, pp. 6232–6237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. M. Stepkowski, W. Chen, J. A. Ross, Z. S. Nagy, and R. A. Kirken, “STAT3: an important regulator of multiple cytokine functions,” Transplantation, vol. 85, no. 10, pp. 1372–1377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. K. M. Dhodapkar, S. Barbuto, P. Matthews et al., “Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma,” Blood, vol. 112, no. 7, pp. 2878–2885, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Herrath, K. Chemin, I. Albrecht, A. I. Catrina, and V. Malmstrom, “Surface expression of CD39 identifies an enriched Treg-cell subset in the rheumatic joint, which does not suppress IL-17A secretion,” European Journal of Immunology, vol. 44, no. 10, pp. 2979–2989, 2014. View at Publisher · View at Google Scholar
  26. K. Sato, “Th17 cells and rheumatoid arthritis—from the standpoint of osteoclast differentiation,” Allergology International, vol. 57, no. 2, pp. 109–114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Hirota, M. Hashimoto, H. Yoshitomi et al., “T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis,” The Journal of Experimental Medicine, vol. 204, no. 1, pp. 41–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. A. S. Basso, H. Cheroutre, and D. Mucida, “More stories on Th17 cells,” Cell Research, vol. 19, no. 4, pp. 399–411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. E. M. Moran, R. Mullan, J. McCormick et al., “Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, oncostatin M and response to biologic therapies,” Arthritis Research & Therapy, vol. 11, no. 4, article R113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. J. L. McGovern, D. X. Nguyen, C. A. Notley, C. Mauri, D. A. Isenberg, and M. R. Ehrenstein, “Th17 cells are restrained by treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy,” Arthritis & Rheumatism, vol. 64, no. 10, pp. 3129–3138, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. A. B. Gottlieb, F. Chamian, S. Masud et al., “TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques,” Journal of Immunology, vol. 175, no. 4, pp. 2721–2729, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. L. C. Zaba, I. Cardinale, P. Gilleaudeau et al., “Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses,” The Journal of Experiment Medicine, vol. 204, no. 13, pp. 3183–3194, 2007. View at Publisher · View at Google Scholar
  33. N. E. Aerts, K. J. de knop, J. Leysen et al., “Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migrationassociated chemokine receptor expression,” Rheumatology, vol. 49, no. 12, pp. 2264–2272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. O. Aravena, B. Pesce, L. Soto et al., “Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-γ-producing NK cell and regulatory T cell subsets,” Immunobiology, vol. 216, no. 12, pp. 1256–1263, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Alzabin, S. M. Abraham, T. E. Taher et al., “Incomplete response of infl ammatory arthritis to blockade is associated with the Th17 pathway,” Annals of the Rheumatic Diseases, vol. 71, no. 10, pp. 1741–1748, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Nadkarni, C. Mauri, and M. R. Ehrenstein, “Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β,” Journal of Experimental Medicine, vol. 204, no. 1, pp. 33–39, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Chaudhry, D. Rudra, P. Treuting et al., “CD4+ regulatory T cells control TH17 responses in a stat3-dependent manner,” Science, vol. 326, no. 5955, pp. 986–991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. X. Valencia, G. Stephens, R. Goldbach-Mansky, M. Wilson, E. M. Shevach, and P. E. Lipsky, “TNF downmodulates the function of human CD4+CD25hi T-regulatory cells,” Blood, vol. 108, no. 1, pp. 253–261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Ranganathan, “Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis,” Pharmacogenomics, vol. 6, no. 5, pp. 481–490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Hagihara, N. Nishimoto, and K. Yoshizaki, “A humanized anti-IL-6 receptor antibody(MRA) in RA therapy,” Nippon Rinsho, vol. 60, no. 12, pp. 2401–2407, 2002. View at Google Scholar · View at Scopus
  41. N. Nishimoto, K. Yoshizaki, N. Miyasaka et al., “Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial,” Arthritis and Rheumatism, vol. 50, no. 6, pp. 1761–1769, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Hosaka, J. Ryu, S. Saitoh, T. Ishii, K. Kuroda, and K. Shimizu, “The combined effects of anti-TNFα antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane,” Cytokine, vol. 32, no. 6, pp. 263–269, 2005. View at Publisher · View at Google Scholar · View at Scopus